This study is for males and females age 18 years or older with symptomatic multiple myeloma. Patient must have had prior treatment with at least one, but no more than three regimens for multiple myeloma. Documented relapse or progressive disease on or after any regimen are eligible. Patient must have achieved a response to at least one prior regimen of therapy. Also, labs will be taken for adequate organ function to determine participation in the study.